Bayer’s New Oncology Chief Wants to Compete for Biotech Deals

Bayer AG is on the lookout for biotech deals as the company seeks to build its pipeline of therapies in the fast-growing field of oncology, anchored by prostate cancer drug Nubeqa.

Bayer will continue to build out its prostate cancer portfolio as well as establish a broader presence in colorectal cancer, for which the company already sells the medicine Stivarga, said Christine Roth, head of Bayer’s oncology strategic business. The company also has early experimental treatments in lung and breast cancer and will focus on its scientific platforms, including targeted radiation therapies, she said.

Bayer is aiming for more ...